Application of combination of PD-1 inhibitor and STING agonist in tumor treatment

A technology for PD-1 and tumor treatment, applied in the field of medicine, can solve the problems of enhancing PD-1 inhibitors and low response rate of PD-1 inhibitors, achieving significant therapeutic effects, improving curative effect, and enhancing expression

Pending Publication Date: 2022-03-11
SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The present invention aims at the problem of low treatment response rate of PD-1 inhibitors in DLBCL, and aims to enhance the curative effect of PD-1 inhibitors in DLBCL through the treatment scheme of PD-1 inhibitors combined with STING agonists. Provide new treatment strategies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of PD-1 inhibitor and STING agonist in tumor treatment
  • Application of combination of PD-1 inhibitor and STING agonist in tumor treatment
  • Application of combination of PD-1 inhibitor and STING agonist in tumor treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0051] experimental method:

[0052] 1. Cell culture. Add 5ml of fetal bovine serum to 50ml of IMDM medium to configure complete IMDM medium. Resuspend LY1 and LY3 cells in IMDM complete medium at 37 °C 5% CO 2 In a cell culture incubator, replace the medium every 2-3 days and pass passage.

[0053] 2. Lentivirus infection for overexpression of STING. Set the infection index (MOI value) to 150, and use IMDM medium to dilute the virus stock solution. Resuspend the cells in complete IMDM medium and inoculate 5x10 cells in a 96-well plate 3 cells / ml, and added the diluted virus and P infection solution respectively. After culturing for 12 hours, gently pipette 50 μl of supernatant and add 50 μl of IMDM complete medium. After 72 hours of infection, the abundance of fluorescent expression was observed. When the abundance reached about 80%, 2 μg / ml puromycin was added for selection, and surviving cells were transferred to culture flasks to continue culturing after 1 week. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a PD-1 inhibitor combined with an STING agonist in tumor treatment, and belongs to the technical field of medicines. According to the application disclosed by the invention, the research finds that both the PD-1 inhibitor (BMS1166) and the STING agonist (DMXAA) can be used for effectively inhibiting the proliferation of DLBCL cells. The DMXAA induces the activation of a cGAS/STING pathway, and promotes the DLBCL cells to highly express STING. The expression of PD-L1 can be promoted by increasing the expression of STING, so that the inhibition of BMS1166 on cell viability is enhanced. Therefore, when the BMS1166 and the DMXAA are combined for use, a synergistic effect can be generated, and a more remarkable anti-tumor effect can be achieved. The invention provides a technical support for enhancing the treatment reaction of the PD-1 inhibitor in DLBCL and optimizing the treatment scheme of the PD-1 inhibitor.

Description

technical field [0001] The invention belongs to the field of medical technology, and in particular relates to the application of PD-1 inhibitors combined with STING agonists in tumor treatment. Background technique [0002] The information disclosed in this background section is only intended to increase the understanding of the general background of the present invention, and is not necessarily taken as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to those skilled in the art. [0003] Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive and heterogeneous non-Hodgkin lymphoma (NHL), the most common subtype of adult B-NHL, with a poor prognosis. Although the new immunotherapy has significantly improved the therapeutic effect and prognosis of patients, 30%-40% of patients are still incurable due to initial treatment refractory, chemotherapy resistance or relapse after remission, and the median survival rate at...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4025A61K31/352A61P35/00
CPCA61K31/4025A61K31/352A61P35/00A61K2300/00
Inventor 周香香王欣蔡怡勍
Owner SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap